Meeder Asset Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Meeder Asset Management’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-6	Closed	-$7K	–	2241
2019 Q1	$7K	Buy	6 +2	+50%	+$2.32K	﹤0.01%	1342
2018 Q4	$4K	Buy	4 +1	+33%	+$1.45K	﹤0.01%	1497
2018 Q3	$4K	Buy	3 +2	+200%	+$2.95K	﹤0.01%	1390
2018 Q2	$966	Buy	+1	New	+$5.49K	﹤0.01%	1497
2018 Q1	–	Hold	0	–	–	–	1355
2017 Q4	–	Hold	0	–	–	–	1469
2017 Q3	–	Hold	0	–	–	–	1600
2017 Q2	–	Hold	0	–	–	–	1478
2017 Q1	–	Hold	0	–	–	–	1129
2016 Q4	–	Hold	0	–	–	–	871

Other funds holding NVIV

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ICM

IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PWM

Paulson Wealth Management Wheaton, Illinois $427M AUM 16.36% 1-Year Est. Return

Meeder Asset Management's NVIV Position: Q2 2019 in Review

Meeder Asset Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2019, closing a stake of 6 shares — an estimated $7K sold.

Meeder Asset Management first reported a position in NVIV in Q2 2018 and held it in 4 quarters. The position peaked at $7K in Q1 2019. 15 funds tracked by Wall St. Rank hold NVIV as of Q2 2019.

Meeder Asset Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2019 after selling out during the quarter.
Meeder Asset Management sold 6 InVivo Therapeutics Holdings Corp shares in Q2 2019, an estimated $7K.
Meeder Asset Management first reported a position in InVivo Therapeutics Holdings Corp in Q2 2018 and held it in 4 quarters.
Meeder Asset Management's InVivo Therapeutics Holdings Corp position peaked at $7K in Q1 2019.
15 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2019.

Based on Meeder Asset Management's 13F filing for Q2 2019, filed 5 Aug 2019.